This flu season is ramping up earlier than last year's, NBC News reports.» Read More
Pfizer earnings topped analysts' expectations on Tuesday, helped by demand for its cancer drugs and medicines in emerging markets.
DuPont reported a 52 percent jump in profit as operating margins rose in five of its seven businesses.
Shares of Sanofi tumbled around 7.4 percent early on Tuesday after the French drugmaker reported weaker-than-expected Q3 sales.
Amgen reported better-than expected quarterly results and said it projects full-year earnings and revenue to come in above analysts' forecasts.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
CNBC's Bertha Coombs discusses how biotech stocks have reached new all-time highs since the sector sold off in the spring.
With some 84 million people in the U.S. struggling with obesity, investing in obesity stocks has become a Wall Street trend.
The roller coaster ride for Sarepta continues, as it's likely to file for approval of its muscular dystrophy drug in mid-2015.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
The FDA wants more data on the new drug, reports CNBC's Meg Tirrell with the latest details.
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.
U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.
The car-service announced a one-day pilot program in partnership with Harvard Medical School to deliver free flu shots on-demand, NBC News reports.
The patient, who was taking Tecfidera, died earlier this month.
GlaxoSmithKline (GSK) reported third-quarter revenue lower than analysts forecast, as sales of blockbuster asthma drug Advair continued to fall.
An experimental trial Ebola vaccine could be in use in West Africa as early as January, the WHO said. NBC News reports.
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee.
Disruption in health care seems to have been a long time coming. Now the sector is innovating, fast.
Out of the headlines from the Ebola hearings, one big takeaway may have been lost: Every U.S. Ebola patient has been treated with at least one investigational product.
AbbVie is reconsidering its takeover of Shire, putting it on track to become the biggest deal to be torpedoed by a crackdown on tax inversions.
Get the best of CNBC in your inbox